Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NGR016 phase II study of NGR-hTNF with or without doxorubicin in advanced soft-tissue sarcoma
2010-018851-88Phase 2Completed
- Sponsor
- MolMed
- Start
- Jul 2010
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of NGR-TNF and doxorubicin in soft tissue sarcoma (STS) (4 arms), sponsored by MolMed. Primary endpoint: 3-month progression-free survival rate. Started Jul 2010; status: completed.
02
Drugs
NGR-TNFdoxorubicin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2010-018851-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018851-88.